{
"id":"mk19_b_en_s2",
"subspecialtyId":"en",
"title":"Disorders of the Pituitary Gland",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s2",
"title":{
"__html":"Disorders of the Pituitary Gland"
},
"titleNode":{
"type":"section-title",
"hlId":"c13c16",
"children":[
"Disorders of the Pituitary Gland"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s2_1",
"title":{
"__html":"Hypothalamic and Pituitary Anatomy and Physiology"
},
"titleNode":{
"type":"section-title",
"hlId":"123dce",
"children":[
"Hypothalamic and Pituitary Anatomy and Physiology"
]
},
"children":[
{
"type":"p",
"hlId":"e2f37f",
"children":[
"The pituitary gland is located in the sella turcica posterior to the sphenoid sinus. The optic chiasm is superior to the pituitary gland, the carotid arteries are lateral, and the pituitary stalk connects the pituitary gland to the hypothalamus ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f03",
"wrapId":"1",
"children":[
"Figure 3"
]
}
]
},
")"
]
},
". The gland is composed of glandular tissue in the anterior pituitary (adenohypophysis) and neural tissue in the posterior pituitary (neurohypophysis). A rich portal vascular network connects the hypothalamus to the anterior pituitary via the pituitary stalk. Stimulatory and inhibitory hormones secreted into the portal blood by the hypothalamus regulate the anterior pituitary. The posterior pituitary hormones are synthesized in the supraoptic and paraventricular nuclei in the hypothalamus and travel through neurons in the stalk to be released in the posterior pituitary gland. The carotid arteries provide blood to the pituitary through the hypophysial arteries, and venous drainage occurs by the petrosal sinuses to the jugular vein."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_f03"
]
},
{
"type":"p",
"hlId":"0f4041",
"children":[
"The anterior pituitary secretes six pituitary hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), adrenocorticotropic hormone (ACTH), prolactin, thyroid-stimulating hormone (TSH), and growth hormone (GH). These six major hormones are regulated by the releasing hormones produced in the hypothalamus. Gonadotropin-releasing hormone (GnRH) is released in pulses and controls LH and FSH. LH and FSH regulate male and female reproduction through stimulation of spermatogenesis and testosterone production in men and stimulation of ovarian follicles and estrogen production in women. Corticotropin-releasing hormone stimulates the production of ACTH in the pituitary from corticotroph cells, which then stimulates cortisol production from the adrenals. Prolactin is synthesized in the lactotroph cells. Its synthesis and secretion is suppressed by hypothalamic dopamine circulation. Thyrotropin-releasing hormone stimulates release of TSH from thyrotroph cells, resulting in synthesis and secretion of TSH. GH release is regulated by GH–releasing hormone (GHRH), which stimulates GH release from somatotroph cells, and somatostatin, which inhibits GH release."
]
},
{
"type":"p",
"hlId":"d62303",
"children":[
"The posterior pituitary gland secretes oxytocin, necessary for parturition and lactation, and antidiuretic hormone, which regulates water balance."
]
},
{
"type":"p",
"hlId":"8d6ba9",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t17",
"wrapId":"2",
"children":[
"Table 17"
]
}
]
},
" lists the pituitary hormones and initial evaluation for suspected pituitary excess or deficiency of each hormone."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_t17"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_2",
"title":{
"__html":"Pituitary Abnormalities"
},
"titleNode":{
"type":"section-title",
"hlId":"334177",
"children":[
"Pituitary Abnormalities"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s2_2_1",
"title":{
"__html":"Incidentally Noted Pituitary Masses"
},
"titleNode":{
"type":"section-title",
"hlId":"7ccafb",
"children":[
"Incidentally Noted Pituitary Masses"
]
},
"children":[
{
"type":"p",
"hlId":"68e65e",
"children":[
"Incidental pituitary lesions discovered on imaging are called “pituitary incidentalomas.” Microadenomas (<1 cm) are common. In patients undergoing MRI for nonpituitary reasons, 10% to 38% of scans show microadenomas whereas in 0.2% show incidental macroadenomas (>1 cm). Most pituitary incidentalomas are benign, nonfunctional pituitary adenomas; however, a small percentage may be Rathke cleft cysts (benign embryologic remnants), craniopharyngiomas, or meningiomas. In patients with a history of malignancy, metastatic disease should be considered."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f588b6",
"children":[
"Most incidentally discovered pituitary masses are benign, nonfunctional pituitary adenomas."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3",
"title":{
"__html":"Empty Sella"
},
"titleNode":{
"type":"section-title",
"hlId":"d9c2be",
"children":[
"Empty Sella"
]
},
"children":[
{
"type":"p",
"hlId":"e621f7",
"children":[
"The term “empty sella” describes a radiologic finding on MRI consisting of an enlarged sella turcica not entirely filled by pituitary tissue. The pituitary gland may be small or compressed, lining the enlarged sella, or may not be visualized. This finding is most often incidental and seen in 8% to 35% of MRIs. The incidence is greater in women with a 5:1 ratio. Primary empty sella is caused by herniation of subarachnoid space and fluid into the sella, compressing the normal pituitary gland. This herniation is caused by sellar diaphragm incompetence, increased intracranial pressure, or volumetric changes in the pituitary gland. Secondary empty sella can be related to pituitary tumor infarction (mostly macroadenomas), infection, autoimmune disease, trauma, or radiotherapy."
]
},
{
"type":"p",
"hlId":"3e7c10",
"children":[
"Although patients with an empty sella usually have normal pituitary function, clinical assessment for signs and symptoms of pituitary deficiencies should be performed. Asymptomatic patients should be screened with prolactin, 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" cortisol, and TSH and free thyroxine (T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
") levels. Additional testing should be based on symptoms. Patients with suspected idiopathic intracranial hypertension should be referred for ophthalmologic evaluation."
]
},
{
"type":"p",
"hlId":"c39c7a",
"children":[
"Asymptomatic patients with empty sella are unlikely to develop hormonal or radiologic changes; however, because of the theoretical risk of progression, repeat endocrine and radiologic evaluation in 24 to 36 months is recommended. If no progression occurs, further evaluation can be limited to those who require it clinically."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"37569d",
"children":[
"Empty sella is diagnosed when the sella turcica is enlarged and not entirely filled with pituitary tissue; all patients with empty sella should have clinical and laboratory assessment for pituitary deficiencies."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_1",
"title":{
"__html":"Other Abnormalities"
},
"titleNode":{
"type":"section-title",
"hlId":"3f2b23",
"children":[
"Other Abnormalities"
]
},
"children":[
{
"type":"p",
"hlId":"86265c",
"children":[
"The pituitary gland can be affected by other pathologic processes, such as trauma, medication side effects, autoimmune disease, infection, infiltrative diseases, metastatic disease, and infarction ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t18",
"wrapId":"3",
"children":[
"Table 18"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_t18"
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_1_1",
"title":{
"__html":"Traumatic Brain Injury"
},
"titleNode":{
"type":"section-title",
"hlId":"5cd719",
"children":[
"Traumatic Brain Injury"
]
},
"children":[
{
"type":"p",
"hlId":"7abc45",
"children":[
"Acute or chronic traumatic brain injury and subarachnoid hemorrhage can cause variable degrees of hypopituitarism, including GH deficiency in up to 50% of patients. These deficiencies can be transient or permanent. Patients with moderate to severe traumatic brain injury, trauma-related findings on initial head CT, symptoms of hormone deficiency, or those with mild traumatic brain injury requiring hospitalization should be evaluated for pituitary hormone deficiency. ACTH deficiency should be evaluated on hospitalization and TSH deficiency evaluated before discharge. All pituitary function (insulin-like growth factor-1 [IGF-1], TSH, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", cortisol, and testosterone in men) should be assessed at 3 to 6 months and then yearly for at least 3 years. Patients with sports-related chronic repetitive head trauma may also benefit from screening for pituitary hormone deficiencies."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_1_2",
"title":{
"__html":"Drug-Induced Abnormalities"
},
"titleNode":{
"type":"section-title",
"hlId":"d15e08",
"children":[
"Drug-Induced Abnormalities"
]
},
"children":[
{
"type":"p",
"hlId":"f31edb",
"children":[
"Exogenously administered hormones provide negative feedback to normal cells in the pituitary gland and suppress endogenous hormone production. Exogenous estrogen or testosterone suppresses the gonadotropins, excess exogenous thyroid hormone suppresses TSH, and physiologic and supraphysiologic doses of glucocorticoids suppress ACTH."
]
},
{
"type":"p",
"hlId":"70cc5f",
"children":[
"Opioids have many effects on pituitary function. Notably, chronic opioid use suppresses gonadotroph function through altered release of GnRH, resulting in hypogonadotropic hypogonadism. Opioids can also increase prolactin release, further inhibiting GnRH secretion. In women, this inhibition may manifest as irregular periods. Men may have signs and symptoms of hypogonadism with laboratory evidence of low testosterone with low or inappropriately normal gonadotropins. Hypogonadism may have long-term consequences, including osteoporosis, muscle loss, and increased adiposity. Guidelines are unclear regarding screening for hypogonadism in patients taking chronic opioid therapy, but discontinuing opioid therapy should result in recovery of gonadal function. If patients cannot discontinue therapy, replacement of estrogen in premenopausal women and testosterone in men is appropriate in absence of contraindications. Opioids also inhibit corticotropin-releasing hormone, reducing the release of ACTH, thereby causing cortisol and dehydroepiandrosterone sulfate deficiency. Rates of adrenal insufficiency in the setting of chronic opioid use range from 9% to 29%; adrenal insufficiency has also been reported in acute opioid treatment. Patients with secondary adrenal insufficiency from opioid treatment should be treated with hydrocortisone. Timing and rate of recovery after opioid cessation are unknown."
]
},
{
"type":"p",
"hlId":"5797bf",
"children":[
"Immune checkpoint inhibitors have been associated with pituitary abnormalities related to hypophysitis. These drugs, including anti-programmed cell death protein-1 (anti-PD-1) agents (nivolumab, pembrolizumab) and anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTL-4) agents (ipilimumab, tremelimumab), are used to treat many solid tumors. Hypophysitis occurs in 0.5% to 17% of patients and often presents with headache and fatigue. It is more common with use of anti-CTL-4 or combination therapy (anti-CTL-4 plus anti-PD-1), in men, and in older patients. Endocrine evaluation usually reveals ACTH, LH, and TSH deficiency, as well as low levels of GH. Imaging demonstrates pituitary gland enhancement or enlargement with pituitary stalk thickening. Diabetes insipidus is uncommon. Treatment includes deficient hormone replacement and high-dose glucocorticoids in severe cases to treat the inflammatory process, although hormone deficiencies often persist."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_2",
"title":{
"__html":"Mass Effects of Pituitary Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"d10e61",
"children":[
"Mass Effects of Pituitary Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"31e36b",
"children":[
"Mass effects of pituitary tumors most commonly include compression of the pituitary gland, resulting in hormone deficiencies, or compression of the optic chiasm, resulting in bitemporal hemianopsia. Other patterns of visual loss can also occur."
]
},
{
"type":"p",
"hlId":"bf1e2d",
"children":[
"Pituitary abnormalities related to gland compression range from an isolated hormone deficiency, most often gonadotropin deficiency, to panhypopituitarism (deficiency of all anterior pituitary hormones). Pituitary stalk compression can lead to hyperprolactinemia through loss of the inhibitory effect of hypothalamic dopamine, which can also contribute to hypogonadism."
]
},
{
"type":"p",
"hlId":"2f2ea8",
"children":[
"Pituitary tumors can have variable effects on compression of surrounding structures. A rapidly growing pituitary tumor or pituitary apoplexy (sudden hemorrhage or infarction of a pituitary adenoma) may result in bitemporal hemianopsia or blindness, caused by optic chiasm compression, or cranial nerve palsies. Conversely, a slow-growing pituitary tumor may cause minimal or no peripheral vision loss because the optic chiasm is able to stretch slowly over the tumor. Given the risk of visual loss, all patients with pituitary tumors that abut or compress the optic chiasm should be evaluated by an ophthalmologist (preferentially a neuro-ophthalmologist). Any abnormality observed on visual examination is an indication for surgery, unless the tumor is a prolactinoma."
]
},
{
"type":"p",
"hlId":"679ff2",
"children":[
"Pituitary tumors can also invade the cavernous sinus but rarely cause mass effect or compression of the carotid within the cavernous sinus. Although headaches can be a symptom of pituitary tumors, they do not correlate well with tumor size and therefore are not typically an indication for surgery."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"eb6887",
"children":[
"Mass effects of pituitary tumors most commonly include compression of the pituitary gland, causing hormone deficiencies, or compression of the optic chiasm with bitemporal hemianopsia."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_3",
"title":{
"__html":"Evaluation of Pituitary Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"009664",
"children":[
"Evaluation of Pituitary Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"8f4b18",
"children":[
"In patients with a pituitary tumor incidentally found on imaging, a dedicated pituitary MRI with and without contrast with dynamic cuts through the sella should be obtained."
]
},
{
"type":"p",
"hlId":"d1759e",
"children":[
"Pituitary hypersecretion should be ruled out in all pituitary incidentalomas by prolactin and IGF-1 measurements; diagnosing a GH-secreting tumor when it is smaller than 1 cm increases the chance of surgical cure. Evaluation for Cushing disease is unnecessary in patients without signs or symptoms of cortisol excess."
]
},
{
"type":"p",
"hlId":"f2d369",
"children":[
"Screening for hypopituitarism is recommended in all pituitary tumors regardless of symptoms, with measurement of FSH, LH, cortisol, TSH, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
", and total testosterone in men. In premenopausal women, a menstrual history can assess for hypogonadotropic hypogonadism. Abnormal baseline testing may prompt further stimulatory testing to confirm hypopituitarism ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t19",
"wrapId":"4",
"children":[
"Table 19"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_en_t19"
]
},
{
"type":"p",
"hlId":"6c0a81",
"children":[
"If a patient does not require surgery for mass effect or pituitary hypersecretion, repeat pituitary hormone assessment and imaging is performed in 6 months for macroadenomas (≥1 cm) and then yearly if no change occurs for at least 3 years before reducing the follow-up frequency."
]
},
{
"type":"p",
"hlId":"0cc22a",
"children":[
"Microadenomas (<1 cm) should be reassessed with imaging in 1 year and then every 1 to 2 years thereafter for at least 3 years before reducing follow-up. Repeat evaluation of pituitary function is unnecessary in microadenomas if initial testing is normal and no change has occurred clinically or in the pituitary MRI (because new pituitary deficiencies typically correlate with change in tumor size on MRI)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"545eab",
"children":[
"Pituitary hypersecretion should be ruled out in patients with pituitary tumors by measurement of prolactin and insulin-like growth factor-1; Cushing disease also should be ruled out if suspected clinically."
]
},
{
"type":"keypoint",
"hlId":"56bea2",
"children":[
"Hypopituitarism should be assessed with follicle-stimulating hormone, luteinizing hormone, cortisol, thyroid-stimulating hormone, free thyroxine, and total testosterone in men with pituitary tumors regardless of symptoms; a menstrual history can assess for hypogonadotropic hypogonadism in premenopausal women."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_3_4",
"title":{
"__html":"Treatment of Clinically Nonfunctioning Pituitary Adenomas"
},
"titleNode":{
"type":"section-title",
"hlId":"649963",
"children":[
"Treatment of Clinically Nonfunctioning Pituitary Adenomas"
]
},
"children":[
{
"type":"p",
"hlId":"45791b",
"children":[
"Patients with a nonfunctioning pituitary adenoma should be referred for neurosurgical evaluation if visual deficits are related to the tumor, the mass abuts or compresses the chiasm or optic nerves on pituitary MRI, or pituitary apoplexy with visual disturbance is present. Women with a macroadenoma close to the optic chiasm who are planning pregnancy may benefit from surgical decompression of the pituitary tumor because of the risk of physiologic enlargement during pregnancy; microadenomas rarely have a clinically significant increase in size during pregnancy. The most common surgical approach for pituitary tumors is transsphenoidal (through the nares or mouth)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"30e221",
"children":[
"Patients with a nonfunctioning pituitary adenoma should be referred for neurosurgical evaluation if visual deficits are related to the tumor, the mass abuts or compresses the chiasm or optic nerves on pituitary MRI, or pituitary apoplexy with visual disturbance is present."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4",
"title":{
"__html":"Pituitary Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"2a93ac",
"children":[
"Pituitary Hormone Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"d670cd",
"children":[
"Hypopituitarism is defined as one or more pituitary hormone deficiencies. It can result from tumor compression of the normal pituitary cells or as a complication of traumatic brain injury, medications, cranial surgery, or radiation therapy. Somatotrophs and gonadotrophs are the most sensitive to injury; therefore, GH, LH, and FSH are the most common pituitary deficiencies. ACTH and TSH deficiencies are less common, but more serious."
]
},
{
"type":"p",
"hlId":"abf173",
"children":[
"Pituitary apoplexy and Sheehan syndrome (pituitary infarction associated with postpartum hemorrhage) can cause acute life-threatening hypopituitarism caused by ACTH deficiency."
]
},
{
"type":"p",
"hlId":"9b47ad",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t20",
"wrapId":"5",
"children":[
"Table 20"
]
}
]
},
" lists the causes of hypopituitarism."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_en_t20"
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_1",
"title":{
"__html":"Panhypopituitarism"
},
"titleNode":{
"type":"section-title",
"hlId":"848357",
"children":[
"Panhypopituitarism"
]
},
"children":[
{
"type":"p",
"hlId":"a549c9",
"children":[
"Panhypopituitarism is a condition in which adequate production of all anterior pituitary hormones is lacking, usually because of a large tumor, apoplexy, or complications of pituitary surgery. Patients require daily replacement of thyroxine and cortisol. Replacement of sex hormones and GH is individualized."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_2",
"title":{
"__html":"Adrenocorticotropic Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"7e03a5",
"children":[
"Adrenocorticotropic Hormone Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"695374",
"children":[
"The most common cause of ACTH deficiency is exogenous glucocorticoid administration and suppression of ACTH production. Oral, intra-articular, and, in some cases, inhaled and topical glucocorticoids can suppress ACTH. Other drugs, including opioids and immune checkpoint inhibitors, have been shown to cause ACTH deficiency. It can also occur in the setting of damage to the pituitary gland after surgery or head trauma. Symptoms of secondary cortisol deficiency include fatigue, weight loss, nausea, dizziness, and hyponatremia. Patients with ACTH deficiency are at lower risk for hypotension and adrenal crisis and have normal potassium levels because of their intact renin-aldosterone systems."
]
},
{
"type":"p",
"hlId":"ef240c",
"children":[
"Morning cortisol (8-9 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
") levels less than 3 μg/dL (82.8 nmol/L) strongly suggest cortisol deficiency; a morning cortisol level greater than 15 μg/dL (414 nmol/L) rules out deficiency. Patients with cortisol levels between 3 and 15 μg/dL (82.8-414 nmol/L) should undergo an ACTH stimulation test (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t19",
"wrapId":"6",
"children":[
"Table 19"
]
}
]
},
")"
]
},
". Because the cortisol assay measures total cortisol (cortisol bound to corticosteroid-binding globulin and free cortisol), testing may be difficult to interpret in low-protein states. After diagnosis, secondary adrenal insufficiency should be treated with hydrocortisone, 15 to 20 mg, in two divided doses. In an emergency setting such as pituitary apoplexy, an immediate intravenous dose of 100 mg of hydrocortisone should be administered."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_en_t19"
]
},
{
"type":"p",
"hlId":"13a2c7",
"children":[
"Glucocorticoid dosing must be adjusted in the setting of physiologic stress or acute illness. Administering two to three times the baseline dose of cortisol replacement for 2 to 3 days is usually sufficient for home management of illness with fever, whereas 25 to 75 mg/day for 1 to 2 days is sufficient for mild to moderate surgical stress. In patients with major physiologic stress, including major surgery or active labor, 100 mg of hydrocortisone should be administered by intravenous injection followed by continuous infusion of 200 mg every 24 hours or a 50-mg intravenous injection every 6 hours (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s3",
"children":[
"Disorders of the Adrenal Glands"
]
},
")."
]
},
{
"type":"p",
"hlId":"9e3f5c",
"children":[
"Patients with iatrogenic secondary adrenal insufficiency require a slow taper of glucocorticoids to allow recovery of the pituitary-adrenal axis. Although short bursts of steroids will not suppress the axis, supraphysiologic doses for 3 weeks will cause suppression. After the glucocorticoid dose is tapered close to physiologic dose (equivalent of 15-20 mg of hydrocortisone), an ACTH test should be performed to evaluate for recovery of the axis. A cortisol level greater than 18 μg/dL (496.8 nmol/L) after ACTH administration demonstrates pituitary-adrenal axis recovery. Despite this recovery, patients may take longer to recover their ability to respond to stress and may require stress-dosing of glucocorticoids in the setting of an illness for up to 1 year."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"278efb",
"children":[
"The most common cause of adrenocorticotropic hormone (ACTH) deficiency is administration of exogenous glucocorticoids and suppression of ACTH production."
]
},
{
"type":"keypoint",
"hlId":"c234b2",
"children":[
"Glucocorticoids prescribed in greater than physiologic doses for 3 weeks or longer should be tapered to allow recovery of the pituitary-adrenal axis; an adrenocorticotropic hormone stimulation test should be performed to assess recovery of the adrenal axis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_3",
"title":{
"__html":"Thyroid-Stimulating Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"f2d20a",
"children":[
"Thyroid-Stimulating Hormone Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"e6863b",
"children":[
"TSH deficiency results in the inability of the thyroid gland to produce free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and triiodothyronine. The diagnosis of secondary hypothyroidism requires measurement of TSH and free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
"; a low free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and a low or inappropriately normal TSH indicates secondary hypothyroidism. The clinical symptoms of secondary hypothyroidism are the same as those with primary hypothyroidism."
]
},
{
"type":"p",
"hlId":"d585e7",
"children":[
"Treatment is daily administration of levothyroxine. Because secondary hypothyroidism is caused by an inability to produce TSH, this hormone cannot be used to monitor therapy and should not be measured after a diagnosis. Free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" should be used to monitor dose adequacy and should be maintained in the mid to upper half of the normal range. Free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" levels can be checked 2 to 3 weeks after a dose change to assess for adequacy in secondary hypothyroidism."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"41ead1",
"children":[
"Diagnosing thyroid-stimulating hormone (TSH) deficiency requires a low free thyroxine and a low or inappropriately normal TSH."
]
},
{
"type":"keypoint",
"hlId":"d4de6a",
"children":[
"Treatment of thyroid-stimulating hormone deficiency is daily levothyroxine; only free thyroxine levels can be used to monitor dose adequacy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_4",
"title":{
"__html":"Gonadotropin Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"ef0a57",
"children":[
"Gonadotropin Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"ac4c4a",
"children":[
"Gonadotropin deficiency can result from pituitary disease or GnRH deficiency, such as in Kallmann syndrome and hypothalamic amenorrhea. Certain drugs, including opioids, can also suppress GnRH. Gonadotropin deficiency results in a decrease of male and female sex hormones. The combination of low or inappropriately normal LH and FSH with low sex hormones is termed “hypogonadotropic hypogonadism.”"
]
},
{
"type":"p",
"hlId":"d3fffc",
"children":[
"Treatment of hypogonadotropic hypogonadism in patients who do not desire fertility can usually be achieved by replacing sex hormones (testosterone in men, estrogen-progesterone in women). Although oral contraceptives may be more acceptable in young women for this purpose, other forms of estrogen and progesterone (estradiol patch with cycled oral progesterone) may be preferred. In men and women who desire fertility, gonadotropin replacement is necessary to stimulate spermatogenesis in men and ovulation in women."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_5",
"title":{
"__html":"Growth Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"22d418",
"children":[
"Growth Hormone Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"64f378",
"children":[
"Because GH is necessary for linear growth, its deficiency in children causes short stature. GH also has other effects on the body, including regulating bone strength, muscle distribution, and mood. Symptoms of adult GH deficiency are subtle and include fatigue, loss of muscle mass, and an increased ratio of fatty tissue to lean mass."
]
},
{
"type":"p",
"hlId":"eeb9bc",
"children":[
"Because idiopathic GH deficiency in adults is rare, only patients with a history of hypothalamic or pituitary disease, surgery or irradiation to these areas, head trauma, or other pituitary hormone deficiencies should be considered for evaluation of adult-onset isolated GH deficiency."
]
},
{
"type":"p",
"hlId":"b85c60",
"children":[
"Because of the pulsatile nature of GH, its deficiency should be assessed through measurement of IGF-1. An IGF-1 level below the normal range for sex and age is highly suggestive of GH deficiency, whereas a normal IGF-1 level does not rule out GH deficiency; therefore, provocative tests (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t17",
"wrapId":"7",
"children":[
"Table 17"
]
}
]
},
")"
]
},
" may be necessary to establish the diagnosis."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_en_t17"
]
},
{
"type":"p",
"hlId":"c07d94",
"children":[
"Treatment benefits in patients with GH deficiency include improvement in exercise capacity, body composition, and bone density. GH is contraindicated in the setting of malignancy or an untreated pituitary tumor because of the potential for stimulation of tumor growth. Additionally, caution should be used in those with diabetes mellitus because treatment may worsen hyperglycemia. When therapy is indicated in adults, GH can be replaced with a low-dose daily injection titrated to a normal age-adjusted IGF-1 level while monitoring for improvement in quality of life, metabolic parameters, bone density, pituitary function, and periodic evaluation of residual pituitary mass. Oral estrogen reduces IGF-1 levels; therefore, transdermal estrogen replacement is preferred in women with GH deficiency."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"4f1807",
"children":[
"Only adults with a history of hypothalamic or pituitary disease, surgery or irradiation to these areas, head trauma, or other pituitary hormone deficiencies should be evaluated for growth hormone deficiency."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_4_6",
"title":{
"__html":"Central Diabetes Insipidus"
},
"titleNode":{
"type":"section-title",
"hlId":"83bf0b",
"children":[
"Central Diabetes Insipidus"
]
},
"children":[
{
"type":"p",
"hlId":"5e90a3",
"children":[
"Inability of the posterior pituitary gland to produce adequate antidiuretic hormone results in central diabetes insipidus (DI). The lack of antidiuretic hormone prevents reabsorption of water in the kidneys, resulting in polyuria and polydipsia. Although significant hypernatremia is rare in patients with an intact thirst mechanism and access to water, it can be severe if patients cannot drink or if they have high-volume nocturia because balancing water loss with intake at night can be difficult. An inappropriately low urine osmolality in the setting of an elevated serum osmolality and hypernatremia in a patient with polyuria (>50 mL/kg/24 hours) is diagnostic of DI. A water deprivation test can be performed when the diagnosis is uncertain, and evaluating the response to desmopressin (DDAVP) can help differentiate central from nephrogenic DI (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t19",
"wrapId":"8",
"children":[
"Table 19"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_en_t19"
]
},
{
"type":"p",
"hlId":"e5efe5",
"children":[
"Central DI is treated with DDAVP administered intranasally, orally, or subcutaneously. Although bioavailability of oral DDAVP is much lower than the other routes of administration, oral preparations are often preferred because intranasal absorption of DDAVP may be altered by changes in nasal mucosa. Doses are usually administered once nightly to prevent nocturia or twice daily if symptoms interfere with daily function; however, caution should be taken to avoid over-replacement, which can cause hyponatremia and volume overload."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"d093a0",
"children":[
"An inappropriately low urine osmolality in the setting of an elevated serum osmolality and hypernatremia in a patient with polyuria (>50 mL/kg/24 h) is diagnostic of diabetes insipidus."
]
},
{
"type":"keypoint",
"hlId":"8387f4",
"children":[
"Central diabetes insipidus is treated with desmopressin."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5",
"title":{
"__html":"Pituitary Hormone Excess"
},
"titleNode":{
"type":"section-title",
"hlId":"1d271f",
"children":[
"Pituitary Hormone Excess"
]
},
"children":[
{
"type":"p",
"hlId":"e710ac",
"children":[
"Pituitary adenomas are considered functional when they secrete pituitary hormones in excess. Although the most common functional pituitary tumors are prolactinomas, pituitary tumors that produce ACTH or GH are important to recognize because of their clinical consequences. TSH-secreting adenomas that cause hyperthyroidism occur very rarely. Pituitary tumors that produce LH or FSH are extremely rare. Pituitary tumors can also rarely co-secrete more than one excess hormone; co-secretion most often occurs with GH and prolactin."
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_1",
"title":{
"__html":"Hyperprolactinemia and Prolactinoma"
},
"titleNode":{
"type":"section-title",
"hlId":"254ece",
"children":[
"Hyperprolactinemia and Prolactinoma"
]
},
"children":[
{
"type":"p",
"hlId":"08267c",
"children":[
"The most common cause of hyperprolactinemia is physiologic and related to pregnancy or lactation. A comprehensive list of causes of hyperprolactinemia is provided in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t21",
"wrapId":"9",
"children":[
"Table 21"
]
}
]
},
". Symptoms of hyperprolactinemia include amenorrhea and, in some cases, galactorrhea. Men often present later with symptoms of mass effect or hypogonadism and less commonly with gynecomastia and breast tenderness."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_en_t21"
]
},
{
"type":"p",
"hlId":"76d8a0",
"children":[
"The most common cause of non–tumor-related hyperprolactinemia is medication. More than 40% of patients taking typical antipsychotics have hyperprolactinemia caused by the dopamine antagonist effect (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t21",
"wrapId":"10",
"children":[
"Table 21"
]
}
]
},
")"
]
},
". Although medication-induced hyperprolactinemia most often results in prolactin levels of 25 to 100 ng/mL (25-100 μg/L), drugs such as metoclopramide, risperidone, and phenothiazines can lead to prolactin levels greater than 200 ng/mL (200 μg/L)."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_en_t21"
]
},
{
"type":"p",
"hlId":"0df175",
"children":[
"Confirming that hyperprolactinemia is related to medication can be challenging. If possible and in consultation with the patient's psychiatrist, prolactin levels should be rechecked after the suspected medication has either been withheld for 3 days or switched to a medication less likely to cause hyperprolactinemia. If the medication cannot be withheld or switched, a pituitary-specific MRI should be performed to ensure that an adenoma is not present. Treating medication-induced hyperprolactinemia with a dopamine agonist is generally not recommended because it can exacerbate psychiatric symptoms. Patients with hypogonadism should be treated with estrogen or testosterone replacement to preserve bone mass."
]
},
{
"type":"p",
"hlId":"437417",
"children":[
"A pituitary MRI is indicated in all patients with unexplained hyperprolactinemia. A prolactin level greater than 100 ng/mL (100 μg/L) suggests microprolactinoma whereas greater than 200 ng/mL (200 μg/L) suggests macroprolactinoma. Because prolactin levels generally correlate with tumor size, a macroadenoma with a prolactin level less than 100 ng/mL (100 μg/L) should raise suspicion of pituitary stalk compression from a nonfunctioning pituitary tumor."
]
},
{
"type":"p",
"hlId":"a5091e",
"children":[
"In patients with macroadenomas, dopamine agonist therapy is recommended to lower prolactin, reduce tumor size, and restore gonadal function. Cabergoline is preferred over bromocriptine because of superior efficacy in lowering prolactin and reducing tumor size. Prolactin can be monitored 4 weeks after initiation of therapy and then every 3 to 4 months once stable. A macroadenoma should be reimaged 3 months after initiation of medical therapy and then every 6 to 12 months until stability is confirmed. Reimaging should be performed if the prolactin level increases despite therapy or if new symptoms develop."
]
},
{
"type":"p",
"hlId":"d70e75",
"children":[
"Patients with asymptomatic microadenomas do not require treatment. Women with hypogonadism related to a microprolactinoma can be treated with a combined oral contraceptive or with a dopamine agonist. MRI should be repeated for a microadenoma in 1 year and then periodically if dopamine agonist therapy is not initiated."
]
},
{
"type":"p",
"hlId":"736d97",
"children":[
"Surgery should only be considered for symptomatic prolactinomas in patients who cannot tolerate dopamine agonist therapy or whose tumors do not shrink or grow while taking dopamine agonist therapy. Recurrence after surgery is common."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f54820",
"hvc":true,
"children":[
"The most common cause of hyperprolactinemia is physiologic, related to pregnancy or lactation."
]
},
{
"type":"keypoint",
"hlId":"c6fdc7",
"hvc":true,
"children":[
"The most common cause of pathologic non–tumor-related hyperprolactinemia is medication."
]
},
{
"type":"keypoint",
"hlId":"46267c",
"hvc":true,
"children":[
"Patients with asymptomatic pituitary microadenomas do not require treatment; for patients with macroadenomas, dopamine agonist therapy is recommended to decrease prolactin, reduce tumor size, and restore gonadal function."
]
},
{
"type":"keypoint",
"hlId":"d43778",
"children":[
"Surgery should only be considered for symptomatic prolactinomas in patients who cannot tolerate dopamine agonist therapy or whose tumors do not respond to dopamine agonist therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_2",
"title":{
"__html":"Prolactinomas and Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"2068e8",
"children":[
"Prolactinomas and Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"cc440d",
"children":[
"Because of lactotroph hyperplasia in pregnancy, prolactinoma enlargement in pregnancy is a concern. Microadenomas are unlikely to enlarge during pregnancy, and dopamine agonist therapy should be discontinued when pregnancy is confirmed. However, patients who have macroadenomas without previous surgical or radiation therapy have a significant risk of tumor growth. Surgical tumor debulking before pregnancy or continuing dopamine agonist therapy (preferably bromocriptine) throughout pregnancy may be required in these patients. If surgery during pregnancy is necessary, the second trimester is the preferred time."
]
},
{
"type":"p",
"hlId":"2e14f1",
"children":[
"Patients with macroadenomas should be monitored with visual field testing each trimester; those with microadenomas can be monitored clinically. Headaches or visual field changes should prompt a noncontrast pituitary MRI to evaluate for change in tumor size."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_3",
"title":{
"__html":"Acromegaly"
},
"titleNode":{
"type":"section-title",
"hlId":"005e83",
"children":[
"Acromegaly"
]
},
"children":[
{
"type":"p",
"hlId":"84d8ee",
"children":[
"Acromegaly is caused by excess GH secretion from a pituitary tumor in 95% of patients. Fewer than 5% of patients with GH excess have a GHRH-secreting tumor or neuroendocrine tumor. When GH-secreting pituitary tumors occur in children before puberty, the result is increased longitudinal growth that results in gigantism. Although gigantism is easily recognized in children, features of excess GH (acromegaly) are more subtle in adults ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t22",
"wrapId":"11",
"children":[
"Table 22"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_en_t22"
]
},
{
"type":"p",
"hlId":"218d9c",
"children":[
"An IGF-1 level should be obtained to evaluate for suspected acromegaly. In patients with an elevated IGF-1 level, an oral glucose tolerance test should be performed to confirm the diagnosis (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t19",
"wrapId":"12",
"children":[
"Table 19"
]
}
]
},
")"
]
},
". When GH excess is demonstrated, a pituitary MRI should be obtained."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_en_t19"
]
},
{
"type":"p",
"hlId":"21e471",
"children":[
"Transsphenoidal resection of the GH-secreting tumor is the mainstay of therapy. Patients who do not achieve remission can be treated with stereotactic irradiation alone or combined with medical therapy. Somatostatin analogues are the medications of choice because they decrease tumor size and lower GH levels. Pegvisomant, a GH receptor antagonist, and dopamine agonists may also be beneficial. After remission is achieved, MRI and IGF-1 levels are monitored annually."
]
},
{
"type":"p",
"hlId":"a838f8",
"children":[
"Patients with acromegaly can have increased mortality risk because of heart disease, sleep apnea, and cancer (especially colon cancer), but this risk returns to baseline when IGF-1 is maintained in the normal range."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c06660",
"children":[
"An insulin-like growth factor-1 level should be obtained to evaluate for suspected acromegaly; in patients with an elevated level, an oral glucose tolerance test should be performed to confirm the diagnosis followed by a pituitary MRI."
]
},
{
"type":"keypoint",
"hlId":"28fd6e",
"children":[
"Transsphenoidal resection of the growth hormone–secreting pituitary tumor is the mainstay of therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_4",
"title":{
"__html":"Thyroid-Stimulating Hormone–Secreting Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"8bba6a",
"children":[
"Thyroid-Stimulating Hormone–Secreting Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"67598f",
"children":[
"TSH-secreting pituitary tumors are extremely rare. These tumors cause signs and symptoms of hyperthyroidism, and laboratory evaluation reveals elevated free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and triiodothyronine levels with an inappropriately normal or elevated TSH level. After other causes of the laboratory abnormalities have been excluded (thyroid assay interference, TSH resistance, or familial dysalbuminemic hyperthyroxinemia), a pituitary MRI should be performed. Transsphenoidal resection of the TSH-producing tumor is the treatment of choice, although medical therapy with somatostatin analogues can be used to control hyperthyroidism before surgery."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_5",
"title":{
"__html":"Excess Antidiuretic Hormone Secretion"
},
"titleNode":{
"type":"section-title",
"hlId":"d39184",
"children":[
"Excess Antidiuretic Hormone Secretion"
]
},
"children":[
{
"type":"p",
"hlId":"50ded8",
"children":[
"The syndrome of inappropriate antidiuretic hormone secretion results in water retention with resultant hyponatremia. Central nervous system disorders (trauma, stroke, brain metastases, infection), drugs, pulmonary disease, and pituitary surgery (3-7 days postoperatively) can result in excess release of antidiuretic hormone. Treatment involves correcting the underlying pathology, fluid restriction, vasopressin receptor antagonists, and hypertonic saline in severe hyponatremia (see ",
{
"type":"cross-reference",
"target":"mk19_a_np_s2_2_1_1",
"children":[
"MKSAP 19 Nephrology"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_5_6",
"title":{
"__html":"Excess Adrenocorticotropic Hormone from Pituitary Source (Cushing Disease)"
},
"titleNode":{
"type":"section-title",
"hlId":"8355f7",
"children":[
"Excess Adrenocorticotropic Hormone from Pituitary Source (Cushing Disease)"
]
},
"children":[
{
"type":"p",
"hlId":"787fa7",
"children":[
"The term “Cushing syndrome” describes hypercortisolism regardless of the cause, whereas “Cushing disease” describes hypercortisolism as a result of excess ACTH secretion from a pituitary tumor. Symptoms and signs of Cushing syndrome are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t23",
"wrapId":"13",
"children":[
"Table 23"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_en_t23"
]
},
{
"type":"p",
"hlId":"1a4817",
"children":[
"The diagnosis of Cushing syndrome is made by first establishing evidence of hypercortisolism (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s3_2_1",
"children":[
"Disorders of the Adrenal Glands"
]
},
"). Measuring ACTH establishes whether it is ACTH-dependent or -independent."
]
},
{
"type":"p",
"hlId":"0db155",
"children":[
"After the diagnosis of ACTH-dependent Cushing syndrome is established, a pituitary MRI is needed for confirmation. If no pituitary tumor is seen or if the tumor is smaller than 6 mm, inferior petrosal sinus sampling is recommended to confirm a pituitary versus ectopic source of ACTH excess. Other dynamic tests that differentiate ectopic from Cushing disease include the high-dose (8-mg) dexamethasone suppression test or corticotropin-releasing hormone stimulation test."
]
},
{
"type":"p",
"hlId":"b784c2",
"children":[
"The treatment of choice for Cushing disease is transsphenoidal resection of the pituitary adenoma. Remission is generally defined by a morning serum cortisol level less than 5 μg/dL (138 nmol/L) within 7 days of surgery. Patients require glucocorticoid replacement postoperatively until the normal corticotroph cells recover from prolonged cortisol suppression. Recovery can take up to 18 months; in some cases corticotroph cells do not recover, necessitating life-long cortisol replacement therapy."
]
},
{
"type":"p",
"hlId":"d9f68a",
"children":[
"If remission is not achieved following surgery, irradiation with or without medical therapy may be required ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t24",
"wrapId":"14",
"children":[
"Table 24"
]
}
]
},
")"
]
},
". Rarely, bilateral adrenalectomy is required in patients unresponsive to all other therapies; these patients require life-long glucocorticoid and mineralocorticoid replacement and carry a risk of pituitary tumor enlargement following adrenalectomy (Nelson syndrome) because of unrestrained stimulation of ACTH production."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_en_t24"
]
},
{
"type":"p",
"hlId":"af6761",
"children":[
"Patients with Cushing disease require imaging and biochemical follow-up (urinary free cortisol or late-night salivary cortisol measurement) annually for several years and then less frequently. Recurrences are managed by repeat transsphenoidal resection, irradiation, or medical therapy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e05e44",
"children":[
"The diagnosis of Cushing syndrome is made by first establishing evidence of hypercortisolism; after adrenocorticotropic hormone–dependent Cushing syndrome is confirmed, a pituitary MRI should be performed."
]
},
{
"type":"keypoint",
"hlId":"b3a15e",
"children":[
"The treatment of choice for adrenocorticotropic hormone–dependent Cushing disease is transsphenoidal resection of the pituitary adenoma."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s2_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361-75. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23471977",
"target":"_blank"
},
"children":[
"PMID: 23471977"
]
},
" doi:10.1210/jc.2012-4075"
]
},
{
"type":"reference",
"children":[
"Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:3888-3921. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27736313",
"target":"_blank"
},
"children":[
"PMID: 27736313"
]
}
]
},
{
"type":"reference",
"children":[
"Freda PU, Beckers AM, Katznelson L, et al; Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894-904. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21474686",
"target":"_blank"
},
"children":[
"PMID: 21474686"
]
},
" doi:10.1210/jc.2010-1048"
]
},
{
"type":"reference",
"children":[
"Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933-51. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25356808",
"target":"_blank"
},
"children":[
"PMID: 25356808"
]
},
" doi:10.1210/jc.2014-2700"
]
},
{
"type":"reference",
"children":[
"Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-88. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21296991",
"target":"_blank"
},
"children":[
"PMID: 21296991"
]
},
" doi:10.1210/jc.2010-1692"
]
},
{
"type":"reference",
"children":[
"Melmed S. Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. N Engl J Med. 2019;380:2551-2562. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31242363",
"target":"_blank"
},
"children":[
"PMID: 31242363"
]
},
" doi:10.1056/NEJMra1817346"
]
},
{
"type":"reference",
"children":[
"Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382:937-950. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32130815",
"target":"_blank"
},
"children":[
"PMID: 32130815"
]
},
" doi:10.1056/NEJMra1810772"
]
},
{
"type":"reference",
"children":[
"Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26222757",
"target":"_blank"
},
"children":[
"PMID: 26222757"
]
},
" doi:10.1210/jc.2015-1818"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t17":{
"id":"mk19_b_en_t17",
"number":17,
"bookId":"en",
"title":{
"__html":"Initial Testing for Pituitary Hormone Deficiency and Excess"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"239071",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 17. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t17"
}
]
},
"Initial Testing for Pituitary Hormone Deficiency and Excess"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d271f",
"class":"col hd c",
"children":[
"Pituitary Hormone Excess"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d78dfe",
"class":"col hd l",
"children":[
"Pituitary Hormone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af479e",
"class":"col hd l",
"children":[
"Peripheral Hormone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"d13b18",
"class":"col hd l",
"children":[
"Initial Test(s)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"daf9d9",
"class":"cell txt l",
"children":[
"ACTH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a10038",
"class":"cell txt l",
"children":[
"Cortisol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c05cb",
"class":"cell txt l",
"children":[
"24-H urine free cortisol (×2)"
]
},
" ",
{
"type":"p",
"hlId":"4e71e8",
"class":"cell txt l",
"children":[
"OR nocturnal salivary cortisol (×2)"
]
},
" ",
{
"type":"p",
"hlId":"224cf2",
"class":"cell txt l",
"children":[
"OR overnight low-dose dexamethasone test"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"4bb43c",
"class":"cell txt l",
"children":[
"Simultaneous serum sodium, serum osmolality, urine sodium, and urine osmolality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6848ae",
"class":"cell txt l",
"children":[
"GH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90f641",
"class":"cell txt l",
"children":[
"IGF-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"90f641",
"class":"cell txt l",
"children":[
"IGF-1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd77cf",
"class":"cell txt l",
"children":[
"TSH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8ffc5",
"class":"cell txt l",
"children":[
"Thyroxine, triiodothyronine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd5bd2",
"class":"cell txt l",
"children":[
"TSH, free (or total) thyroxine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9af47e",
"class":"cell txt l",
"children":[
"PRL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58eb84",
"class":"cell txt l",
"children":[
"Prolactin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"58eb84",
"class":"cell txt l",
"children":[
"Prolactin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a93ac",
"class":"col hd c",
"children":[
"Pituitary Hormone Deficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d78dfe",
"class":"col hd l",
"children":[
"Pituitary Hormone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af479e",
"class":"col hd l",
"children":[
"Peripheral Hormone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d13b18",
"class":"col hd l",
"children":[
"Initial Test(s)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a8a09",
"class":"col hd l",
"children":[
"Confirmatory Test",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"daf9d9",
"class":"cell txt l",
"children":[
"ACTH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a10038",
"class":"cell txt l",
"children":[
"Cortisol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de315e",
"class":"cell txt l",
"children":[
"Simultaneous 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" ACTH, cortisol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f7157",
"class":"cell txt l",
"children":[
"ACTH stimulation test"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ca57a",
"class":"cell txt l",
"children":[
"Simultaneous serum sodium, urine and serum osmolality"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acc261",
"class":"cell txt l",
"children":[
"Water deprivation test"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5027c8",
"class":"cell txt l",
"children":[
"LH and FSH",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36a041",
"class":"cell txt l",
"children":[
"Testosterone or estradiol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fabf15",
"class":"cell txt l",
"children":[
"Simultaneous LH, FSH, 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" total testosterone (male), estradiol (female)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd77cf",
"class":"cell txt l",
"children":[
"TSH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8ffc5",
"class":"cell txt l",
"children":[
"Thyroxine, triiodothyronine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f6b54",
"class":"cell txt l",
"children":[
"Simultaneous TSH, free (or total) thyroxine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6848ae",
"class":"cell txt l",
"children":[
"GH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90f641",
"class":"cell txt l",
"children":[
"IGF-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90f641",
"class":"cell txt l",
"children":[
"IGF-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"975e07",
"class":"cell txt l",
"children":[
"GHRH-arginine"
]
},
" ",
{
"type":"p",
"hlId":"04d6f4",
"class":"cell txt l",
"children":[
"Insulin tolerance"
]
},
" ",
{
"type":"p",
"hlId":"2bc9ce",
"class":"cell txt l",
"children":[
"Glucagon stimulation"
]
},
" ",
{
"type":"p",
"hlId":"501371",
"class":"cell txt l",
"children":[
"Ghrelin agonist stimulation"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACTH = adrenocorticotropic hormone; ADH = antidiuretic hormone; FSH = follicle-stimulating hormone; GH = growth hormone; GHRH = growth hormone–releasing hormone; IGF-1 = insulin-like growth factor 1; LH = luteinizing hormone; PRL = prolactin; TSH = thyroid-stimulating hormone."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"See Table 19 for additional information on confirmatory testing for pituitary dysfunction."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Routine testing for deficiency is not recommended without specific signs of deficiency, such as amenorrhea, gynecomastia, or impotence."
]
]
},
"mk19_b_en_t18":{
"id":"mk19_b_en_t18",
"number":18,
"bookId":"en",
"title":{
"__html":"Other Pituitary Abnormalities"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f8d688",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 18. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t18"
}
]
},
"Other Pituitary Abnormalities"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50fc9b",
"class":"col hd l",
"children":[
"Cause"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f14d8",
"class":"col hd l",
"children":[
"Mass Effect"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6755e6",
"class":"col hd l",
"children":[
"Most Common Hormone Deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44562a",
"class":"col hd l",
"children":[
"Clinical Context"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"d90f22",
"class":"col hd l",
"children":[
"Inflammation/Infection"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5592d0",
"class":"cell txt l",
"children":[
"Lymphocytic hypophysitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"daf9d9",
"class":"cell txt l",
"children":[
"ACTH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60d689",
"class":"cell txt l",
"children":[
"Pregnancy, postpartum"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7b2da",
"class":"cell txt l",
"children":[
"Meningitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da8cc9",
"class":"cell txt l",
"children":[
"Anterior pituitary hormones and ADH deficiencies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52251d",
"class":"cell txt l",
"children":[
"Immunocompromised patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8b4bf",
"class":"cell txt l",
"children":[
"Checkpoint inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"daf9d9",
"class":"cell txt l",
"children":[
"ACTH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8faa3",
"class":"cell txt l",
"children":[
"Immunotherapy for cancer treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cfdf5",
"class":"col hd l",
"children":[
"Neoplastic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"caa311",
"class":"cell txt l",
"children":[
"Pituitary metastasis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b18070",
"class":"cell txt l",
"children":[
"Breast (most common), lung, lymphoma, renal cell"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff58ad",
"class":"cell txt l",
"children":[
"Pituitary carcinoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6ee12",
"class":"cell txt l",
"children":[
"Hypersecretion more common than deficiencies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfd4c7",
"class":"cell txt l",
"children":[
"0.1% of all pituitary tumors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8947dc",
"class":"cell txt l",
"children":[
"Craniopharyngioma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6ce16",
"class":"cell txt l",
"children":[
"Anterior pituitary hormones and ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc9e27",
"class":"cell txt l",
"children":[
"Most often seen in children"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"83a87e",
"class":"col hd l",
"children":[
"Infiltrative"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c57e04",
"class":"cell txt l",
"children":[
"Sarcoidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6ce16",
"class":"cell txt l",
"children":[
"Anterior pituitary hormones and ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27a1fe",
"class":"cell txt l",
"children":[
"Occurs in up to 10% of patients with sarcoidosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"290ad9",
"class":"cell txt l",
"children":[
"Hemochromatosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"988cc3",
"class":"cell txt l",
"children":[
"Gonadotropin deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0f7ed",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HFE"
]
},
" gene mutation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c94d95",
"class":"cell txt l",
"children":[
"Langerhans cell histiocytosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b50976",
"class":"cell txt l",
"children":[
"ADH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc9e27",
"class":"cell txt l",
"children":[
"Most often seen in children"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACTH = adrenocorticotropic hormone; ADH = antidiuretic hormone."
]
]
},
"mk19_b_en_t19":{
"id":"mk19_b_en_t19",
"number":19,
"bookId":"en",
"title":{
"__html":"Dynamic Testing for Pituitary Dysfunction"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0736f6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 19. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t19"
}
]
},
"Dynamic Testing for Pituitary Dysfunction"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc66",
"class":"col hd l",
"children":[
"Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"22a700",
"class":"col hd l",
"children":[
"Technique"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed5f9d",
"class":"col hd l",
"children":[
"Interpretation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c618b",
"class":"cell txt l",
"children":[
"ACTH (cortisol) deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f7157",
"class":"cell txt l",
"children":[
"ACTH stimulation test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c02cf",
"class":"cell txt l",
"children":[
"Measure baseline serum cortisol and ACTH level."
]
},
" ",
{
"type":"p",
"hlId":"7f7237",
"class":"cell txt l",
"children":[
"Administer 250 μg of synthetic ACTH IM or IV."
]
},
" ",
{
"type":"p",
"hlId":"216a41",
"class":"cell txt l",
"children":[
"Measure cortisol levels at 30 and 60 minutes."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4daa7",
"class":"cell txt l",
"children":[
"Serum cortisol level >18 μg/dL (496.8 nmol/L) at any measurement indicates a normal response."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0db453",
"class":"cell txt l",
"children":[
"ADH deficiency (DI)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42a5da",
"class":"cell txt l",
"children":[
"Water deprivation test, followed by desmopressin challenge, if indicated"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f38bd2",
"class":"cell txt l",
"children":[
"Patient empties bladder, and baseline weight is measured. Start test at 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
"."
]
},
" ",
{
"type":"p",
"hlId":"eb8a3a",
"class":"cell txt l",
"children":[
"Measure urine volume and osmolality hourly."
]
},
" ",
{
"type":"p",
"hlId":"45cc7b",
"class":"cell txt l",
"children":[
"Measure serum sodium, osmolality, and weight every 2 h."
]
},
" ",
{
"type":"p",
"hlId":"b4b57f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"The test is stopped after 8 h or when one of the following occurs:"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"fb72b3",
"class":"cell txt li",
"children":[
"Urine osmolality/plasma osmolality is >2"
]
},
" ",
{
"type":"p",
"hlId":"3f70dd",
"class":"cell txt li",
"children":[
"Patient has lost >3% of body weight"
]
},
" ",
{
"type":"p",
"hlId":"30f04c",
"class":"cell txt li",
"children":[
"Urine osmolality is stable for 2-3 h while serum osmolality rises"
]
},
" ",
{
"type":"p",
"hlId":"caa06b",
"class":"cell txt li",
"children":[
"Plasma osmolality >295 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
},
" ",
{
"type":"p",
"hlId":"8fa27a",
"class":"cell txt li",
"children":[
"Serum sodium >145 mEq/L (145 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7f901",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Water deprivation test interpretation:"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"d07772",
"class":"cell txt li",
"children":[
"Urine osmolality >800 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O is a normal response to water deprivation, indicating ADH production and peripheral effect are intact."
]
},
" ",
{
"type":"p",
"hlId":"7bba9c",
"class":"cell txt li",
"children":[
"Serum osmolality >295 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O and/or serum sodium >145 mEq/L (145 mmol/L) with inappropriately dilute urine (urine osmolality/plasma osmolality <2) is diagnostic of DI."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d59ddc",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Desmopressin challenge:"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"eb4ab8",
"class":"cell txt li",
"children":[
"If final urine osmolality <600 mOsm/kg, serum osmolality >295 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O, or serum sodium >145 mEq/L (145 mmol/L): give desmopressin 2 μg subcutaneously."
]
},
" ",
{
"type":"p",
"hlId":"656bfa",
"class":"cell txt li",
"children":[
"Measure urine osmolality and urine volume hourly for 4 h after desmopressin."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9ff598",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Desmopressin challenge interpretation:"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"08db4a",
"class":"cell txt li",
"children":[
"Urine osmolality >800 mOsm/kg after desmopressin is consistent with complete central DI."
]
},
" ",
{
"type":"p",
"hlId":"9d2e2d",
"class":"cell txt li",
"children":[
"No increase in urine osmolality (remains <300 mOsm/kg) is diagnostic of complete nephrogenic DI."
]
},
" ",
{
"type":"p",
"hlId":"386826",
"class":"cell txt li",
"children":[
"Urine osmolality between 300 and 800 mOsm is consistent with partial DI"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cefe2",
"class":"cell txt l",
"children":[
"Growth hormone excess (acromegaly)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"355dc3",
"class":"cell txt l",
"children":[
"Glucose tolerance test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6fbae",
"class":"cell txt l",
"children":[
"75-g oral glucose tolerance test. Measure glucose and GH at 0, 30, 60, 90, 120, and 150 minutes."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7643f7",
"class":"cell txt l",
"children":[
"GH <0.2 ng/mL (0.2 μg/L) is a normal response."
]
},
" ",
{
"type":"p",
"hlId":"9fc831",
"class":"cell txt l",
"children":[
"GH nadir ≥1.0 ng/mL (1.0 μg/L) (or ≥0.3 ng/mL [0.3 μg/L] on an ultrasensitive assay) is diagnostic of acromegaly."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACTH = adrenocorticotropic hormone; ADH = antidiuretic hormone; DI = diabetes insipidus; GH = growth hormone; IM = intramuscular; IV = intravenous."
]
]
},
"mk19_b_en_t20":{
"id":"mk19_b_en_t20",
"number":20,
"bookId":"en",
"title":{
"__html":"Causes of Hypopituitarism"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1dfa5e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 20. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t20"
}
]
},
"Causes of Hypopituitarism"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cfdf5",
"class":"col hd l",
"children":[
"Neoplastic"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7e5ae",
"class":"cell txt l",
"children":[
"Pituitary adenoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7ca3b",
"class":"cell txt l",
"children":[
"Meningioma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8947dc",
"class":"cell txt l",
"children":[
"Craniopharyngioma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"104a47",
"class":"cell txt l",
"children":[
"Metastatic cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5feaae",
"class":"cell txt l",
"children":[
"Lymphoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a62020",
"class":"col hd l",
"children":[
"Infiltrative Disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c57e04",
"class":"cell txt l",
"children":[
"Sarcoidosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"290ad9",
"class":"cell txt l",
"children":[
"Hemochromatosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c94d95",
"class":"cell txt l",
"children":[
"Langerhans cell histiocytosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd4d5d",
"class":"col hd l",
"children":[
"Inflammation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5592d0",
"class":"cell txt l",
"children":[
"Lymphocytic hypophysitis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e4926",
"class":"col hd l",
"children":[
"Iatrogenic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cc2ab",
"class":"cell txt l",
"children":[
"Surgery"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bff9b6",
"class":"cell txt l",
"children":[
"Radiation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b58d88",
"class":"col hd l",
"children":[
"Congenital Deficiencies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f32a2",
"class":"col hd l",
"children":[
"Vascular"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5d712",
"class":"cell txt l",
"children":[
"Pituitary infarction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ade35",
"class":"cell txt l",
"children":[
"Pituitary apoplexy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9c2be",
"class":"col hd l",
"children":[
"Empty Sella"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"08de74",
"class":"col hd l",
"children":[
"Hypothalamic Disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5cd719",
"class":"col hd l",
"children":[
"Traumatic Brain Injury"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba25cf",
"class":"col hd l",
"children":[
"Medications"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_6-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"394a71",
"class":"cell txt l",
"children":[
"Opioids"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_6-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b4b453",
"class":"cell txt l",
"children":[
"Checkpoint inhibitors: nivolumab, ipilimumab, tremelimumab, pembrolizumab"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_en_t21":{
"id":"mk19_b_en_t21",
"number":21,
"bookId":"en",
"title":{
"__html":"Causes of Hyperprolactinemia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"5cb292",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 21. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t21"
}
]
},
"Causes of Hyperprolactinemia"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a8d37",
"class":"col hd l",
"children":[
"Physiologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"col hd l",
"children":[
"Other"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96b3ba",
"class":"cell txt l",
"children":[
"Coitus"
]
},
" ",
{
"type":"p",
"hlId":"ef8fb9",
"class":"cell txt l",
"children":[
"Exercise"
]
},
" ",
{
"type":"p",
"hlId":"463643",
"class":"cell txt l",
"children":[
"Lactation"
]
},
" ",
{
"type":"p",
"hlId":"c0b197",
"class":"cell txt l",
"children":[
"Nipple stimulation"
]
},
" ",
{
"type":"p",
"hlId":"0b1e9b",
"class":"cell txt l",
"children":[
"Pregnancy"
]
},
" ",
{
"type":"p",
"hlId":"243924",
"class":"cell txt l",
"children":[
"Sleep"
]
},
" ",
{
"type":"p",
"hlId":"43e350",
"class":"cell txt l",
"children":[
"Stress"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de15a9",
"class":"cell txt l",
"children":[
"Antipsychotics"
]
},
" ",
{
"type":"p",
"hlId":"30930b",
"class":"cell txt li",
"children":[
"Typical antipsychotics"
]
},
" ",
{
"type":"p",
"hlId":"b6d375",
"class":"cell txt lii",
"children":[
"Chlorpromazine"
]
},
" ",
{
"type":"p",
"hlId":"761d45",
"class":"cell txt lii",
"children":[
"Fluphenazine"
]
},
" ",
{
"type":"p",
"hlId":"af9209",
"class":"cell txt lii",
"children":[
"Haloperidol"
]
},
" ",
{
"type":"p",
"hlId":"2a3897",
"class":"cell txt lii",
"children":[
"Prochlorperazine"
]
},
" ",
{
"type":"p",
"hlId":"e99cd7",
"class":"cell txt li",
"children":[
"Atypical antipsychotics"
]
},
" ",
{
"type":"p",
"hlId":"0ab51b",
"class":"cell txt lii",
"children":[
"Amisulpride"
]
},
" ",
{
"type":"p",
"hlId":"cdfda2",
"class":"cell txt lii",
"children":[
"Olanzapine (rarely)"
]
},
" ",
{
"type":"p",
"hlId":"3e1fdc",
"class":"cell txt lii",
"children":[
"Paliperidone"
]
},
" ",
{
"type":"p",
"hlId":"1b254d",
"class":"cell txt lii",
"children":[
"Risperidone"
]
},
" ",
{
"type":"p",
"hlId":"c01555",
"class":"cell txt lii",
"children":[
"Ziprasidone (rarely)"
]
},
" ",
{
"type":"p",
"hlId":"352975",
"class":"cell txt l",
"children":[
"SSRIs"
]
},
" ",
{
"type":"p",
"hlId":"9f9256",
"class":"cell txt li",
"children":[
"Citalopram"
]
},
" ",
{
"type":"p",
"hlId":"433b69",
"class":"cell txt li",
"children":[
"Escitalopram"
]
},
" ",
{
"type":"p",
"hlId":"a0f638",
"class":"cell txt li",
"children":[
"Fluoxetine"
]
},
" ",
{
"type":"p",
"hlId":"00016c",
"class":"cell txt li",
"children":[
"Paroxetine"
]
},
" ",
{
"type":"p",
"hlId":"a4b119",
"class":"cell txt li",
"children":[
"Sertraline"
]
},
" ",
{
"type":"p",
"hlId":"c7e7f0",
"class":"cell txt l",
"children":[
"Antihypertensives"
]
},
" ",
{
"type":"p",
"hlId":"ae1243",
"class":"cell txt li",
"children":[
"Methyldopa"
]
},
" ",
{
"type":"p",
"hlId":"275377",
"class":"cell txt li",
"children":[
"Verapamil"
]
},
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"cell txt l",
"children":[
"Other"
]
},
" ",
{
"type":"p",
"hlId":"ca350a",
"class":"cell txt li",
"children":[
"Cimetidine"
]
},
" ",
{
"type":"p",
"hlId":"bf4574",
"class":"cell txt li",
"children":[
"Domperidone"
]
},
" ",
{
"type":"p",
"hlId":"a9ece1",
"class":"cell txt li",
"children":[
"Estrogen"
]
},
" ",
{
"type":"p",
"hlId":"dceb60",
"class":"cell txt li",
"children":[
"Metoclopramide"
]
},
" ",
{
"type":"p",
"hlId":"394a71",
"class":"cell txt li",
"children":[
"Opioids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb07f1",
"class":"cell txt l",
"children":[
"Chest wall trauma"
]
},
" ",
{
"type":"p",
"hlId":"0c9768",
"class":"cell txt l",
"children":[
"Chronic kidney disease"
]
},
" ",
{
"type":"p",
"hlId":"f21b78",
"class":"cell txt l",
"children":[
"Cirrhosis"
]
},
" ",
{
"type":"p",
"hlId":"0a1541",
"class":"cell txt l",
"children":[
"Cocaine"
]
},
" ",
{
"type":"p",
"hlId":"35cb76",
"class":"cell txt l",
"children":[
"Empty sella syndrome"
]
},
" ",
{
"type":"p",
"hlId":"146d12",
"class":"cell txt l",
"children":[
"Herpes zoster"
]
},
" ",
{
"type":"p",
"hlId":"e0eff6",
"class":"cell txt l",
"children":[
"Polycystic ovary syndrome"
]
},
" ",
{
"type":"p",
"hlId":"7ed14a",
"class":"cell txt l",
"children":[
"Prolactinoma"
]
},
" ",
{
"type":"p",
"hlId":"ac24a7",
"class":"cell txt l",
"children":[
"Seizures"
]
},
" ",
{
"type":"p",
"hlId":"0d274a",
"class":"cell txt l",
"children":[
"Severe hypothyroidism"
]
},
" ",
{
"type":"p",
"hlId":"2c0483",
"class":"cell txt l",
"children":[
"Stalk compression"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"SSRI = selective serotonin reuptake inhibitor."
]
]
},
"mk19_b_en_t22":{
"id":"mk19_b_en_t22",
"number":22,
"bookId":"en",
"title":{
"__html":"Features of Acromegaly"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0e0a04",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 22. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t22"
}
]
},
"Features of Acromegaly"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8db97a",
"class":"col hd l",
"children":[
"Clinical Signs and Symptoms"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b40f4",
"class":"cell txt l",
"children":[
"Prognathism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9b20e",
"class":"cell txt l",
"children":[
"Macroglossia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3a6fc",
"class":"cell txt l",
"children":[
"Wide-spaced teeth (typically the first sign of growth hormone excess)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3e51d",
"class":"cell txt l",
"children":[
"Wide nose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"516ed1",
"class":"cell txt l",
"children":[
"Enlarged and swollen hands and feet"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71ed94",
"class":"cell txt l",
"children":[
"Increased sweating"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83fe2d",
"class":"cell txt l",
"children":[
"Skin tags"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dedc1a",
"class":"cell txt l",
"children":[
"Joint pain"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5234f",
"class":"cell txt l",
"children":[
"Headache"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58f50c",
"class":"col hd l",
"children":[
"Disease Associations"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fede4",
"class":"cell txt l",
"children":[
"Sleep apnea"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0770f6",
"class":"cell txt l",
"children":[
"Insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05f0a4",
"class":"cell txt l",
"children":[
"Hypertrophic cardiomyopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"82c00a",
"class":"cell txt l",
"children":[
"Colon polyps and colon cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ead112",
"class":"cell txt l",
"children":[
"Thyroid nodules and thyroid cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b06fc",
"class":"cell txt l",
"children":[
"Valvular heart disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a9d74",
"class":"cell txt l",
"children":[
"Arthropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3779ce",
"class":"cell txt l",
"children":[
"Carpal tunnel syndrome"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_en_t23":{
"id":"mk19_b_en_t23",
"number":23,
"bookId":"en",
"title":{
"__html":"Symptoms and Signs of Cushing Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d705c7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 23. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t23"
}
]
},
"Symptoms and Signs of Cushing Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd2968",
"class":"col hd l",
"children":[
"Symptoms"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75cde5",
"class":"cell txt l",
"children":[
"Depression"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5ff1b",
"class":"cell txt l",
"children":[
"Fatigue"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"343c74",
"class":"cell txt l",
"children":[
"Rapid weight gain"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6aa590",
"class":"cell txt l",
"children":[
"Decreased libido"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"229831",
"class":"cell txt l",
"children":[
"Menstrual abnormalities"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4713b5",
"class":"col hd l",
"children":[
"Signs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff6377",
"class":"cell txt l",
"children":[
"Striae (especially if reddish purple and >1 cm wide)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c95ec",
"class":"cell txt l",
"children":[
"Easy bruising",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32e493",
"class":"cell txt l",
"children":[
"Facial plethora",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"445156",
"class":"cell txt l",
"children":[
"Muscle weakness (proximal myopathy)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88ca74",
"class":"cell txt l",
"children":[
"Abdominal obesity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab4164",
"class":"cell txt l",
"children":[
"Skin tears (secondary to thinning of the epidermis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78ebea",
"class":"cell txt l",
"children":[
"Acne"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4226cb",
"class":"cell txt l",
"children":[
"Hirsutism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9196ab",
"class":"cell txt l",
"children":[
"Dorsocervical fat pad (buffalo hump)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"760eb0",
"class":"cell txt l",
"children":[
"Supraclavicular fat pad",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e32a97",
"class":"cell txt l",
"children":[
"Hypokalemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05159a",
"class":"cell txt l",
"children":[
"Diabetes mellitus"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Features that best discriminate Cushing syndrome from the general population."
]
]
},
"mk19_b_en_t24":{
"id":"mk19_b_en_t24",
"number":24,
"bookId":"en",
"title":{
"__html":"Medication Management for Treatment of Cushing Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"340351",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 24. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t24"
}
]
},
"Medication Management for Treatment of Cushing Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a519d4",
"class":"col hd l",
"children":[
"Steroidogenesis Inhibitors (Inhibits Cortisol Synthesis)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8c270",
"class":"col hd l",
"children":[
"Pituitary Directed (Inhibits ACTH Secretion)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19f327",
"class":"col hd l",
"children":[
"Glucocorticoid Receptor Antagonist (Inhibits Cortisol Action)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a8f84",
"class":"cell txt l",
"children":[
"Osilodrostat"
]
},
" ",
{
"type":"p",
"hlId":"85246d",
"class":"cell txt l",
"children":[
"Ketoconazole"
]
},
" ",
{
"type":"p",
"hlId":"0ec352",
"class":"cell txt l",
"children":[
"Metyrapone"
]
},
" ",
{
"type":"p",
"hlId":"89dd3f",
"class":"cell txt l",
"children":[
"Mitotane"
]
},
" ",
{
"type":"p",
"hlId":"dc3ea2",
"class":"cell txt l",
"children":[
"Etomidate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e190dd",
"class":"cell txt l",
"children":[
"Pasireotide"
]
},
" ",
{
"type":"p",
"hlId":"f49355",
"class":"cell txt l",
"children":[
"Cabergoline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47237d",
"class":"cell txt l",
"children":[
"Mifepristone"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACTH = adrenocorticotropic hormone."
]
]
}
}
}